Profile data is unavailable for this security.
About the company
PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.
- Revenue in USD (TTM)3.33m
- Net income in USD-65.70m
- Incorporated2015
- Employees90.00
- LocationPureTech Health PLC6 Tide Street, Suite 400BOSTON 02210United StatesUSA
- Phone+1 (617) 482-2333
- Fax+1 (617) 482-3337
- Websitehttps://puretechhealth.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Evolus Inc | 219.70m | -60.00m | 709.38m | 279.00 | -- | 38.26 | -- | 3.23 | -1.05 | -1.05 | 3.82 | 0.2962 | 1.14 | 3.86 | 7.62 | 804,750.90 | -31.06 | -40.92 | -40.14 | -59.74 | 69.28 | 65.43 | -27.31 | -80.46 | 2.96 | -2.90 | 0.8674 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Pliant Therapeutics Inc | 248.00k | -170.74m | 711.84m | 158.00 | -- | 1.63 | -- | 2,870.34 | -2.86 | -2.86 | 0.0042 | 7.25 | 0.0004 | -- | 0.0701 | 1,569.62 | -30.50 | -33.24 | -32.04 | -35.39 | -- | -- | -68,847.98 | -360.29 | -- | -- | 0.0642 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -57.95m | 720.06m | 50.00 | -- | 2.30 | -- | -- | -2.25 | -2.25 | 0.00 | 8.07 | 0.00 | -- | -- | 0.00 | -28.45 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| SAGE Therapeutics Inc | 91.06m | -503.14m | 722.18m | 487.00 | -- | 1.02 | -- | 7.93 | -8.40 | -8.40 | 1.52 | 11.73 | 0.0916 | -- | 6.26 | 186,989.70 | -50.61 | -21.88 | -54.64 | -23.30 | 96.49 | 99.63 | -552.52 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| Taysha Gene Therapies Inc | 14.16m | -118.01m | 742.46m | 52.00 | -- | 13.79 | -- | 52.45 | -1.19 | -1.19 | 0.0896 | 0.2879 | 0.1112 | -- | -- | 272,230.80 | -92.70 | -- | -146.13 | -- | -- | -- | -833.60 | -- | -- | -- | 0.4315 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Nuvation Bio Inc | 0.00 | -68.87m | 746.46m | 159.00 | -- | 1.11 | -- | -- | -0.3146 | -0.3146 | 0.00 | 2.71 | 0.00 | -- | -- | 0.00 | -10.84 | -16.27 | -11.09 | -16.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.25 | -- | -- | -- |
| Hillevax Inc | 0.00 | -143.51m | 750.29m | 90.00 | -- | 3.10 | -- | -- | -3.29 | -3.29 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -46.66 | -- | -50.34 | -- | -- | -- | -- | -- | -- | -- | 0.0963 | -- | -- | -- | 22.68 | -- | -- | -- |
| GeneDx Holdings Corp | 221.85m | -135.02m | 752.62m | 1.00k | -- | 3.63 | -- | 3.39 | -5.25 | -5.25 | 8.60 | 7.93 | 0.4721 | 9.16 | 7.27 | 221,849.00 | -28.73 | -- | -35.07 | -- | 50.57 | 11.50 | -60.86 | -121.10 | 2.99 | -130.27 | 0.2015 | -- | -13.69 | 8.72 | 67.98 | -- | 7.77 | -- |
| Scholar Rock Holding Corp | 0.00 | -183.26m | 753.68m | 150.00 | -- | 4.12 | -- | -- | -2.09 | -2.09 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.98 | -38.14 | -70.72 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2151 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| Wave Life Sciences Ltd | 112.91m | -61.67m | 762.93m | 266.00 | -- | 30.02 | -- | 6.76 | -0.5152 | -0.5152 | 0.9985 | 0.2719 | 0.4494 | -- | -- | 424,488.70 | -24.54 | -56.98 | -60.43 | -102.38 | -- | -- | -54.61 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| Dianthus Therapeutics Inc | 3.22m | -50.21m | 763.09m | 53.00 | -- | 2.05 | -- | 236.69 | -3.20 | -3.20 | 0.2721 | 12.70 | 0.0138 | -- | -- | 60,830.19 | -21.56 | -41.40 | -22.27 | -44.70 | -- | -- | -1,557.51 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| PureTech Health PLC (ADR) | 3.33m | -65.70m | 763.63m | 90.00 | -- | -- | -- | 229.32 | -2.36 | -2.36 | 0.1195 | -- | 0.0048 | -- | 0.4676 | 37,000.00 | -9.54 | 4.92 | -10.67 | 5.94 | -- | -- | -2,000.84 | 352.67 | -- | -- | 0.0524 | 0.00 | -78.68 | -30.64 | -30.47 | -- | -44.10 | -- |
| CARGO Therapeutics Inc | 0.00 | -121.21m | 766.56m | 116.00 | -- | 1.76 | -- | -- | -2.91 | -2.91 | 0.00 | 9.48 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Viridian Therapeutics Inc | 288.00k | -218.13m | 793.95m | 96.00 | -- | 2.07 | -- | 2,756.78 | -4.50 | -4.50 | 0.0058 | 9.13 | 0.0006 | -- | 2.50 | 3,063.83 | -42.89 | -55.59 | -45.38 | -60.32 | -- | -- | -75,737.84 | -5,678.12 | -- | -- | 0.0337 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
| Cogent Biosciences Inc | 0.00 | -212.17m | 805.54m | 164.00 | -- | 4.02 | -- | -- | -2.47 | -2.47 | 0.00 | 4.42 | 0.00 | -- | -- | 0.00 | -57.40 | -49.53 | -62.27 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| Aurinia Pharmaceuticals Inc | 191.41m | -62.56m | 808.06m | 300.00 | -- | 2.26 | -- | 4.22 | -0.4363 | -0.4363 | 1.34 | 2.50 | 0.3953 | 0.6008 | 7.98 | 638,023.30 | -12.92 | -25.97 | -14.63 | -28.24 | 88.78 | -- | -32.69 | -137.64 | 5.05 | -- | 0.1843 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
Data as of Jun 13 2024. Currency figures normalised to PureTech Health PLC's reporting currency: US Dollar USD
0.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Pentwater Capital Management LPas of 31 Mar 2024 | 17.00k | 0.06% |
| AWM Investment Co., Inc.as of 31 Mar 2024 | 6.90k | 0.03% |
| Tower Research Capital LLCas of 31 Mar 2024 | 137.00 | 0.00% |
| UBS Financial Services, Inc.as of 31 Mar 2024 | 20.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
